USPH Form 4: CEO Christopher Reading Sells 2,000 Shares at $83.53
USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share.
Rhea-AI Filing Summary
USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share. After the sale he beneficially owns 114,088 shares in total. The filing discloses that 34,098 of those shares were granted as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan, with a detailed vesting schedule listing tranche dates and share counts through March 6, 2029, contingent on continued employment.
Positive
- Detailed disclosure of restricted stock tranches totaling 34,098 shares with exact vesting dates through March 6, 2029
- Clear reporting of insider status: Christopher J. Reading is identified as Chairman of the Board and CEO and filed individually
Negative
- Insider sale of 2,000 shares on 09/04/2025 at $83.53 per share
- No details in the filing about the purpose of the sale or any Rule 10b5-1 plan designation
Insights
TL;DR: Reporting person sold a small block of shares and retains a substantial position including time‑vested restricted stock.
The Form 4 records a disposition of 2,000 shares at $83.53, reducing the immediate holding but leaving 114,088 shares beneficially owned. The filing clearly itemizes that 34,098 shares are restricted stock with a multi‑year vesting schedule through March 6, 2029, contingent on continued employment. From a disclosure perspective this is routine insider activity: it shows liquidity taken by an executive while maintaining a significant retained stake and scheduled future vesting.
TL;DR: Transaction is a routine insider sale; vesting schedule is explicitly disclosed.
The document provides specific compliance information: the reporting person is both Chairman and CEO and filed as an individual reporting person. The Form 4 includes the transaction code (S) for sale and the remaining beneficial ownership total. It also discloses the number of restricted shares and precise vesting tranches, which aids transparency on potential future insider stock availability. No amendments or additional derivative positions are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,000 | $83.53 | $167K |
Footnotes (1)
- F1. Includes 34,098 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 4,152 shares on each of November 20, 2025 and March 6, 2026, 2,902 shares on each of May 20, 2026, August 20, 2026, November 20, 2026, and March 6, 2027, 2,277 shares on each of May 20, 2027, August 20, 2027, and November 20, 2027, 2,285 shares on March 6, 2028,1,265 shares on each of May 20, 2028, August 20, 2028, and November 20, 2028, and 1,275 shares on March 6, 2029, if he is an employee of the Company on those dates.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Christopher J. Reading report on Form 4 for USPH?
Was the Form 4 filed jointly or by one reporting person?
Does the Form 4 report any derivative securities or option transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.